TY - JOUR AU - Abraira, Laura AU - López-Maza, Samuel AU - Quintana, Manuel AU - Fonseca, Elena AU - Toledo, Manuel AU - Campos-Fernández, Daniel AU - Lallana, Sofía AU - Grau-López, Laia AU - Ciurans, Jordi AU - Jiménez, Marta AU - Becerra, Juan Luis AU - Bustamante, Alejandro AU - Rubiera, Marta AU - Penalba, Anna AU - Montaner, Joan AU - Álvarez Sabin, José AU - Santamarina, Estevo TI - Exploratory study of blood biomarkers in patients with post-stroke epilepsy JF - EUROPEAN STROKE JOURNAL J2 - EU STROKE J PY - 2024 SN - 2396-9873 DO - 10.1177/23969873241244584 UR - https://m2.mtmt.hu/api/publication/34766579 ID - 34766579 LA - English DB - MTMT ER - TY - JOUR AU - Molnár, Tihamér TI - Subarachnoidalis vérzés intenzív osztályos kezelése: úton a személyre szabott medicina felé JF - FOCUS MEDICINAE J2 - FOCUS MEDICINAE VL - 25 PY - 2024 IS - 3 SP - 15 EP - 18 PG - 4 SN - 1419-0478 UR - https://m2.mtmt.hu/api/publication/34569393 ID - 34569393 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Batista, S. AU - Bocanegra-Becerra, J.E. AU - Claassen, B. AU - Rubião, F. AU - Rabelo, N.N. AU - Figueiredo, E.G. AU - Oberman, D.Z. TI - Biomarkers in aneurysmal subarachnoid hemorrhage: A short review JF - World neurosurgery: X VL - 19 PY - 2023 SN - 2590-1397 DO - 10.1016/j.wnsx.2023.100205 UR - https://m2.mtmt.hu/api/publication/34480100 ID - 34480100 N1 - Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru Department of Neurosurgery, University of São Paulo, São Paulo, Brazil Department of Neurosurgery, Hospital de Força Aérea do Galeão, Rio de Janeiro, Brazil Export Date: 05 January 2024; Cited By: 1; Correspondence Address: D.Z. Oberman; Neurosurgery Department Hospital Força Aérea do Galeão, Estrada do Galeão, Rio de Janeiro - RJ, 4101 - Galeão, 21941-353, Brazil; email: saviobatista@ufrj.br LA - English DB - MTMT ER - TY - JOUR AU - Cardinale, Christopher J. AU - Abrams, Debra J. AU - Mentch, Frank D. AU - Cardinale, John A. AU - Wang, Xiang AU - Kao, Charlly AU - Sleiman, Patrick M. A. AU - Hakonarson, Hakon TI - Elevated Levels of the Cytokine LIGHT in Pediatric Crohn’s Disease JF - JOURNAL OF IMMUNOLOGY J2 - J IMMUNOL VL - 210 PY - 2023 IS - 5 SP - 590 EP - 594 PG - 5 SN - 0022-1767 DO - 10.4049/jimmunol.2200652 UR - https://m2.mtmt.hu/api/publication/33638416 ID - 33638416 N1 - Export Date: 8 May 2023 CODEN: JOIMA AB - LIGHT (homologous to lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry mediator, a receptor expressed by T lymphocytes), encoded by the TNFSF14 gene, is a cytokine belonging to the TNF superfamily. On binding to its receptors, herpes virus entry mediator and lymphotoxin β receptor, it activates inflammatory responses. We conducted this study to determine whether plasma LIGHT levels are elevated in Crohn’s disease (CD) in a pediatric population with the aim of nominating this cytokine as a therapeutic target. We used a single-molecule immunoassay to determine the circulating levels of free LIGHT in plasma from pediatric patients with CD in our biobank (n = 183), a panel of healthy pediatric (n = 9) or adult (n = 22) reference samples, and pediatric biobank controls (n = 19). We performed correlational analyses between LIGHT levels and the clinical characteristics of the CD cohort, including age, Montreal classification, family history, medical/surgical therapy, and routine blood test parameters. LIGHT levels were greatly elevated in CD, with an average of 305 versus 32.4 pg/ml for controls from the biobank (p < 0.0001). The outside reference samples showed levels of 57 pg/ml in pediatric controls and 55 pg/ml in adults (p < 0.0001). We found a statistically significant correlation between white blood cell count and free LIGHT (p < 0.046). We conclude that free, soluble LIGHT is increased 5- to 10-fold in pediatric CD across an array of disease subtypes and characteristics. LA - English DB - MTMT ER - TY - JOUR AU - Wu, Yangying AU - Zhao, Ziya AU - Kang, Shaolei AU - Zhang, Lijuan AU - Lv, Fajin TI - Potential application of peripheral blood biomarkers in intracranial aneurysms JF - FRONTIERS IN NEUROLOGY J2 - FRONT NEUR VL - 14 PY - 2023 SN - 1664-2295 DO - 10.3389/fneur.2023.1273341 UR - https://m2.mtmt.hu/api/publication/34206076 ID - 34206076 N1 - Funding Agency and Grant Number: The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article. Funding text: We would like to express our sincere gratitude to the individuals who generously provided their expertise and suggestions for the completion of this review.r The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article. LA - English DB - MTMT ER - TY - JOUR AU - Spántler, Dóra AU - Csécsei, Péter AU - Böröcz, Katalin AU - Berki, Tímea AU - Zavori, Laszlo AU - Schwarcz, Attila AU - Lenzsér, Gábor AU - Molnár, Tihamér TI - Serum Periostin May Help to Identify Patients with Poor Collaterals in the Hyperacute Phase of Ischemic Stroke JF - DIAGNOSTICS J2 - DIAGNOSTICS VL - 12 PY - 2022 IS - 8 PG - 11 SN - 2075-4418 DO - 10.3390/diagnostics12081942 UR - https://m2.mtmt.hu/api/publication/33050416 ID - 33050416 N1 - Department of Anaesthesiology and Intensive Care and Department of Neurosurgery, Medical School, University of Pecs, Pecs, 7624, Hungary Department of Neurosurgery, Medical School, University of Pecs, Pecs, 7624, Hungary Department of Immunology and Biotechnology, Medical School, University of Pecs, Pecs, 7624, Hungary Salisbury NHS Foundation Trust, Salisbury, SP2 8BJ, United Kingdom Export Date: 13 November 2023 Correspondence Address: Csecsei, P.; Department of Neurosurgery, Hungary; email: csecseipeti@yahoo.com AB - Background: Periostin is a glycoprotein that mediates cell functions in the extracellular matrix and appears to be a promising biomarker in neurological damage, such as ischemic stroke (IS). We aimed to measure serum periostin levels in the hyperacute phase of ischemic stroke to explore its predictive power in identification of patients with poor collaterals (ASPECT < 6). Methods: We prospectively enrolled 122 patients with acute ischemic stroke within the first 6 h after onset. The early ischemic changes were evaluated by calculating ASPECT score on admission using a native CT scan. An unfavorable outcome was defined as the modified Rankin Scale (mRS) > 2 at 90 days follow-up. Blood samples were collected on admission immediately after CT scan and periostin serum concentrations were determined by ELISA. Results: The admission concentration of serum periostin was significantly higher in patients with unfavorable outcome than in patients with favorable outcome (615 ng/L, IQR: 443–1070 vs. 390 ng/L, 260–563, p < 0.001). In a binary logistic regression model, serum periostin level was a significant predictor for ASPECT < 6 status on admission, within 6 h after stroke onset (OR, 5.911; CI, 0.990–0.999; p = 0.015). Conclusion: Admission periostin levels can help to identify patients who are not suitable for neurointervention, especially if advanced neuroimaging is not available. LA - English DB - MTMT ER - TY - JOUR AU - Molnár, Tihamér AU - Ezer, Erzsébet TI - Neurointenzív Tanszék – az első év JF - FOCUS MEDICINAE J2 - FOCUS MEDICINAE VL - 23 PY - 2021 IS - 1 SP - 3 EP - 5 PG - 3 SN - 1419-0478 UR - https://m2.mtmt.hu/api/publication/31963966 ID - 31963966 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Schranz, Dániel AU - Molnár, Tihamér AU - Erdő-Bonyár, Szabina AU - Simon, Diána AU - Berki, Tímea AU - Závori, László AU - Szolics, Alex AU - Büki, András AU - Lenzsér, Gábor AU - Csécsei, Péter TI - Fatty Acid-Binding Protein 3 and CXC-Chemokine Ligand 16 are Associated with Unfavorable Outcome in Aneurysmal Subarachnoid Hemorrhage JF - JOURNAL OF STROKE AND CEREBROVASCULAR DISEASES J2 - J STROKE CEREBROVASC DIS VL - 30 PY - 2021 IS - 11 PG - 7 SN - 1052-3057 DO - 10.1016/j.jstrokecerebrovasdis.2021.106068 UR - https://m2.mtmt.hu/api/publication/32165067 ID - 32165067 N1 - * Megosztott szerzőség AB - Aneurysmal subarachnoid hemorrhage (aSAH) is associated with activation of the inflammatory cascade contributing to unfavorable outcome and secondary complications, such as delayed cerebral ischemia (DCI). Both fatty acid-binding protein 3 (FABP3) and CXC-chemokine ligand 16 (CXCL-16) have been linked to vascular inflammation and cellular death. The authors aimed to assess the 30-day prognostic value of serum levels of FABP3 and CXCL-16 and explore their associations with DCI in aSAH patients.A total of 60 patients with aSAH were prospectively enrolled. Sampling for markers was done at 24 hours after the index event. FABP3 and CXCL-16 serum concentrations were determined by MilliPlex multiplex immunoassay method. The primary endpoint was unfavorable outcome at Day 30 based on the modified Rankin Scale.Both FABP3 and CXCL-16 levels were significantly elevated in patients with unfavorable outcome compared to those with favorable outcome after aSAH (FABP3: 2133 pg/mL, IQR: 1053-4567 vs. 3773, 3295-13116; p<0.003 and CXCL-16: 384 pg/mL, 313-502 vs. 498, 456-62, p<0.001). The area under the curve (AUC) for serum CXCL-16 levels as a predictor of unfavorable outcome at Day 30 was 0.747 (95% CI =0.622-0.871; p<0.001). Based on binary logistic regression analysis, serum CXCL-16 with a cut-off level >446.7 ng/L independently predicted Day 30 unfavorable outcome with a sensitivity of 81% and a specificity of 62%. Neither CXCL-16 nor FABP3 showed a significant correlation with DCI.Early FABP3 and CXCL-16 levels are significantly associated with poor 30-day outcome in patients with aSAH. LA - English DB - MTMT ER -